deltatrials
Recruiting PHASE2 INTERVENTIONAL 13-arm NCT05283720

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma

Sponsor: AbbVie

Conditions Non-Hodgkin Lymphoma
Interventions CC-99282 Cyclophosphamide Doxorubicin Hydrochloride [HCl] Epcoritamab Ibrutinib Lenalidomide Polatuzumab Vedotin Prednisone Rituximab
Updated 42 times since 2022 Last updated: Mar 2, 2026 Started: Jun 14, 2022 Primary completion: Nov 30, 2032 Completion: Nov 30, 2032
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Non-Hodgkin Lymphoma and is currently actively recruiting participants. AbbVie leads this study, which shows 42 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~Jul 2025 · 3 months · monthly snapshot~Jul 2025 – ~Aug 2025 · 31 days · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – ~Jan 2026 · 31 days · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 4 months · monthly snapshot

Change History

42 versions recorded

  1. Mar 2026 — Present [monthly]

    Recruiting PHASE2

  2. Feb 2026 — Mar 2026 [monthly]

    Recruiting PHASE2

  3. Jan 2026 — Feb 2026 [monthly]

    Recruiting PHASE2

  4. Dec 2025 — Jan 2026 [monthly]

    Recruiting PHASE2

  5. Nov 2025 — Dec 2025 [monthly]

    Recruiting PHASE2

▶ Show 37 earlier versions

  1. Oct 2025 — Nov 2025 [monthly]

    Recruiting PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE2

  3. Aug 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

    Phase: PHASE1/PHASE2 → PHASE2

  4. Jul 2025 — Aug 2025 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE2 → PHASE1/PHASE2

  5. Apr 2025 — Jul 2025 [monthly]

    Recruiting PHASE2

  6. Mar 2025 — Apr 2025 [monthly]

    Recruiting PHASE2

  7. Feb 2025 — Mar 2025 [monthly]

    Recruiting PHASE2

  8. Jan 2025 — Feb 2025 [monthly]

    Recruiting PHASE2

  9. Dec 2024 — Jan 2025 [monthly]

    Recruiting PHASE2

  10. Nov 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

  11. Oct 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  12. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE2

  13. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  14. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE2

  15. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  16. May 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  17. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE2

  18. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE2

  19. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE2

  20. Jan 2024 — Feb 2024 [monthly]

    Recruiting PHASE2

  21. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE2

  22. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  23. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  24. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  25. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  26. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  27. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  28. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  29. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

  30. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  31. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  32. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE2

  33. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  34. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  35. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  36. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  37. Apr 2022 — Jul 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
  • Genmab
Data source: Genmab

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aarhus, Denmark , Amsterdam, Netherlands , Atlanta, United States , Augsburg, Germany , Badalona, Spain , Baltimore, United States , Barcelona, Spain , Beijing, China , Brno, Czechia and 57 more locations